PSA, which is overexpressed in prostate carcinoma, represents a molecular target for selectively releasing an anticancer agent from a prodrug formulation. In this study, we report on the in vivo antitumor efficacy of an efficacious albumin-binding prodrug of doxorubicin (PSA9) that incorporates p-aminobenzyloxycarbonyl (PABC) as a self-immolative spacer in addition to the heptapeptide, Arg-Ser-Ser-Tyr-Tyr-Ser-Leu, which serves as a substrate for PSA. The prodrug is cleaved very efficiently by PSA releasing H-Ser-Leu-PABC-doxorubicin and subsequently doxorubicin in PSA-positive cell lysates and prostate tumor homogenates as the final cleavage product. PSA9 at 3 Â 6 mg kg À1 doxorubicin equivalents (intravenous) was compared with conventional doxorubicin at equitoxic doses (at 3 Â 3 mg kg À1 ; intravenous) in an orthotopic mouse model of prostate cancer using LNCaP lentiviral luciferase-neomycin cells transduced with luciferase. Whereas doxorubicin did not show any efficacy against the primary tumor or metastases, the prodrug reduced the primary tumor by 30-50% and circulating PSA levels, and in addition, showed a pronounced reduction in lung and bone metastases by B77% and B96%, respectively, and a positive trend regarding the activity against liver and lymph-node metastases compared with control and doxorubicin-treated animals. The incorporation of PABC as a self-immolative spacer together with a PSA substrate demonstrates superior antitumor effects over doxorubicin attributed to an efficient cleavage by PSA releasing doxorubicin as the final active agent in prostate tumor homogenates. Using this approach for developing effective prodrugs against prostate cancer, is worthy of further preclinical optimization.
Introduction
Prostate cancer is one of the leading causes of cancerrelated death in men and remains incurable in the metastatic setting, especially after the formation of osteoblastic bone metastases that remain the most lethal aspect of prostate cancer. 1, 2 Despite the initial response to androgen deprivation, the disease gradually progresses to a hormone-refractory state as a result of cumulative genetic alterations in tumor cells or the microenvironment. At present, there is no effective therapy for men with hormone-resistant metastatic prostate cancer, and among the approved anticancer agents, taxotere, mitoxantrone and estramustine phosphate, the best results are achieved with taxotere. 3 Recent data obtained from two large phase III clinical trials, TAX327 and SWOG 9916, indicated that taxotere supplemented with prednisone can achieve a survival benefit in some patients with hormone-resistant metastatic prostate cancer, whereas treatment with mitoxantrone supplemented with corticosteroids alleviated symptoms but did not improve overall patient survival. [4] [5] [6] Thus, the benefit of therapy with antineoplastic agents is limited because of systemic toxicity and lack of tumor selectivity, and there is an urgent medical need to design drug delivery systems, which transport the anticancer agent to the primary and metastatic tumors.
In the past, we along with others have developed lowor high-molecular-weight prodrugs that are cleaved by PSA, a serine protease that is overexpressed in metastatic prostate carcinoma. [7] [8] [9] These prodrugs were developed with the aim of reducing toxicity and improving both the efficacy and the selectivity of chemotherapeutic agents for treating hormone-refractory prostate cancer.
Over the last decade, we have intensively investigated human serum albumin (HSA) as a drug carrier which is having an increasing role in the clinical setting for delivering anticancer drugs to the tumor. 10 Uptake of albumin in tumors is mediated by the EPR effect, that is, the enhanced permeability and retention of macromolecules in relation to passive tumor targeting. 11 Our tumortargeting strategy that exploits albumin as a drug carrier is based on two features: (1) in situ binding of a thiolbinding prodrug to the cysteine-34 position of circulating albumin after intravenous administration with subsequent accumulation of the drug albumin conjugate in the tumor due to passive targeting and (2) release of the albumin-bound drug at the tumor site due to the incorporation of a cleavable bond between the drug and the carrier. Anthracyclines, such as doxorubicin, have frequently been used by us for the development of such albumin-binding prodrugs. 12 The first and most advanced prototype of these prodrugs is the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (abbreviated DOXO-EMCH, now , an acid-sensitive prodrug of doxorubicin that is under phase II clinical development 13 (also see http://www.cytrx.com). Inspired by the translational research with DOXO-EMCH, we developed a PSA-cleavable albumin-binding prodrug of doxorubicin, that is, EMC-Arg-Ser-Ser-TyrTyr-Ser-Arg-DOXO (abbreviated PSA5, Figure 1a) . 9 PSA5 was shown to rapidly bind to the circulating albumin and was superior over doxorubicin in an orthotopic PSApositive model (LNCaP) with respect to antitumor efficacy on the primary tumor but showed some but not statistically significant activity only against lung metastases. 9 The major drawback of this prodrug was that although it was cleaved efficiently by PSA, it liberated the less active doxorubicin dipeptide H-SerArg-DOXO as the major cleavage product, which only showed marginal cleavage to H-Arg-DOXO or doxorubicin in tumor homogenates of PSA-positive LNCAP tumors.
Thus, to exploit the full potential of our prodrug approach, we developed an optimized albumin-binding prodrug of doxorubicin (abbreviated PSA9, Figure 1b) , which releases doxorubicin effectively as the final cleavage product. PSA9 combines a PSA-cleavable peptide substrate with p-aminobenzyloxycarbonyl (PABC) as a self-immolative spacer.
PSA9 exhibited good water solubility (B4 mg ml À1 in isotonic 5% glucose solution), was bound rapidly to the cysteine-34 position of circulating HSA, and its albuminbound form (HSA9) was cleaved efficiently by PSA releasing H-Ser-Leu-PABC-DOXO. 14 This doxorubicin dipeptide was further degraded in LNCaP prostate tumor tissue homogenates and in PSA-positive LNCaP luciferase-neomycin cell lysates to release doxorubicin as a final cleavage product within few hours by adventitious proteases.
14 After cleavage and deacylation, the PABC spacer decomposes in 1,6-benzylelimination and spontaneously releases the free drug. 15 Moreover, the dipeptide H-Ser-Leu-PABC-DOXO was significantly more active against a PSA-expressing prostate cancer cell line (LNCaP lentiviral luciferaseneomycin (LLN)) than either H-Ser-Arg-DOXO, the cleavage product of PSA5, or H-Ser-Leu-DOXO that both do not contain the PABC spacer.
14 As a consequence and as a main goal of this study, we set out to investigate the antitumor efficacy of PSA9 in comparison with conventional doxorubicin in a mouse model of human prostate cancer using luciferasetransduced LNCaP cells orthotopically implanted in the prostate of severe combined immunodeficiency (SCID) mice. As the LNCaP LLN cell line used in this study was genetically altered to express luciferase, tumor growth could be followed in vivo, and bone, lung, liver and inguinal lymph nodes as the most susceptible organs for the formation of metastases in progressive prostate cancer could be analysed using an in vitro luciferase assay.
Materials and methods
All animal experiments were performed in accordance with the German Animal License Regulations (Tierschutzgesetz) identical to the United Kingdom Coordinating Committee on Cancer Research guidelines for the welfare of animals in experimental neoplasia. 9, 16 Male SCID (C.B-17/IcrHanHsd-Prkdc-scid) mice were Germany) . To test novel antitumor agents in a setting that reflects the human disease better than subcutaneous models, we used our previously designed orthotopic model for prostate cancer using PSA-positive luciferasemarked LNCaP luciferase-neomycin tumor cells orthotopically implanted into the prostates of SCID mice. 9 Moreover, to optimize sensitivity, we used high luciferase-expressing LNCaP LLN cell pools, which were generated by transduction using a VSV-G-pseudotyped lentivirus.
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Generation of luciferase-expressing LNCaP LLN cells
The luciferase-neomycin fusion gene cassette was inserted into a lentiviral backbone vector, 17, 18 using BsRGi/SnaBI replacing the original expression cassette. The 293T cells were transfected with this lentiviral backbone and plasmids pCMV VSV-G (encoding the vesicular stomatitis virus surface gene) and pCMV (GAG/REV) using Ca-phosphate precipitates. Fortyeight and seventy-two hours later, viral supernatants were harvested, filtered through 0.4-mM filters and added to LNCaP cells together with 4 mg ml À1 polybrene. The supernatants were left for ca. 8 h and exchanged for normal medium. Transduced LNCaP LLN cells were selected using 3 mg ml À1 G418 for 1 week and used as a cell pool. This protocol yielded cell pools with B10 times higher levels of luciferase activity than the previously reported retroviral vector (LNCaP luciferase-neomycin: ca. 800 LU (light units) per cell versus LNCaP LLN: ca. 10 000 LU per cell).
Orientating toxicity studies
To estimate the maximum tolerated dose of our novel prodrug PSA9, we intravenously injected 4 groups of healthy male C.B-17/SCID mice (3 animals each) with 6, 8, 12 and 24 mg kg À1 doxorubicin equivalents of PSA9 as the albumin-binding prodrug. The doses were injected on days 1, 8 and 15. Body weight, as an indicator for drug toxicity, was recorded three times per week. On day 24, the toxicity study was terminated and animals were killed.
In vivo animal experiment
Male SCID (C.B-17/Icr-HanHsd-Prkdc-scid) mice ranging between 6 and 8 weeks of age (approximate weight, 30 g) were housed under controlled conditions. They were fed a diet consisting of not o20% proteins, 5% fibers, 3.5% fats and 6.5% ashes and supplied with vitamins mixture and water ad libitum and exposed to 12-h light and dark cycle before experiments. The animals were maintained in separated conventional housing at constant temperature and humidity and kept in the animal house for 2 weeks for adaptation.
Animal model design
Mice were anesthetized with isofluorane, positioned and fixed on the back. The coat of the abdominal area was shaved and the skin was disinfected with 70% alcohol. A 3-4 mm incision was made alongside the linea alba in the lower abdomen using the cranial edge of the bladder for orientation. Seminal vesicles and prostate were pulled out partially and exposed carefully. In all, 2 Â 10 6 tumor cells, suspended in 20 ml phosphate-buffered saline, were injected into the anterior part of the prostate using a 29-G needle syringe. The exteriorized organs were reinserted into the abdomen, the abdominal wall was closed using 5-0 Dexon sutures (Dexon, B. Braun-Dexon, Spangenberg, Germany), and the skin was again disinfected using a Dibromol tincture (Trommsdorf GmbH, Alsdorf, Germany).
Measurement of in vivo bioluminescence
Animals were injected with 100 ml of D-luciferin (Synchem OHG, Felsberg/Altenburg, Germany) and anesthetized using isofluorane. Ten minutes after the injection, images of mice were acquired using a NIGHTOWL camera (Berthold Technologies, Bad Wildbad, Germany) equipped with isofluorane adaptors. An overview picture of the mice and 2 exposures, 5 min at 10 Â 10 binning and 1 min at 2 Â 2 binning, were taken. The intensity of the emitted light was quantified over the whole animal using the software provided with the NIGHTOWL CCD camera (Berthold Technologies) and expressed as photons per second.
Necropsy and luciferase assays of mouse organs
At the end of the experiment, mice were killed, the abdominal cavity was opened and a picture of the tumor in situ was taken. The primary tumor was resected, weighed, measured and its volume was calculated using the formula V ¼a 2 Â A/2 (a: small diameter, A: large diameter). Tumors were subsequently homogenized in a luciferase lysis buffer. To obtain a quantitative analysis of the metastatic spread into potential target organs, the lung, liver, inguinal lymph nodes and lumbar spine, as the most common metastatic sites in prostate cancer, were resected from the animals taking great care to prevent cross-contamination of the tissues. After homogenization, the insoluble material was removed by centrifugation for 10 min at 3000 r.p.m. in a Heraeus Megafuge 2.0 (Thermo Scientific, Karlsruhe, Germany). In all, 5 ml was checked for protein concentration using a Bradford assay (Sigma B6916, Sigma, Seelze, Germany) with bovine serum albumin serving as a standard protein and 10 ml was measured in a luciferase assay (Promega E4550, Promega, Mannheim, Germany).
Results and Discussion
Orientating toxicity studies revealed that a noticeable weight loss of 420% between day 1 and day 8 was observed in animals treated with 12 and 24 mg kg À1 doxorubicin equivalents of PSA9. In addition, one animal of each group was found dead on day 8. Therefore, treatment with these two doses was stopped. Treatment with 8 mg kg À1 doxorubicin equivalents of PSA9 administered as the albumin-binding prodrug also induced a weight loss of B20% between day 1 and day 10. In addition, one of the three animals in this group was found dead on day 12. On the other hand, no significant weight loss was observed in the group treated with 6 mg kg À1 doxorubicin equivalents of PSA9, and all the three animals of this group survived without any signs of toxicity up to the end of the experiment (day 24).
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Treatment of SCID mice orthotopically implanted with LNCaP LLN cells
On preliminary toxicity studies, 3 Â 6 mg kg À1 doxorubicin equivalents of PSA9 were compared with 3 Â 3 mg kg À1 of free doxorubicin in a dose schedule illustrated in Table 1 .
The doses of doxorubicin were lower than those used in the previously reported experiment for PSA5 (2 Â 4 mg kg À1 ) 9 as 2 of the 10 treated animals died in this group and body weight loss exceeded 20%. The maximum tolerated dose of PSA9 over PSA5 was twofold lower, which is very likely because of the improved cleavage profile of PSA9 that effectively releases active doxorubicin as the final cleavage product. A group receiving 5% glucose solution served as a negative control.
Ten days after orthotopic implantation of LNCaP LLN cells, the in vivo growth of tumor cells was first measured using bioluminescence (BLI). Another 14 days later, mice were randomized into treatment groups according to their in vivo BLI signals, and mice without detectable tumors were excluded from the study. The take rate was B60%, underlining the importance of using high luciferase-expressing LNCaP LLN cells and BLI for ensuring that only tumor-bearing animals are included in the in vivo study. Both body weights and clinical symptoms of animals were recorded three times weekly.
After 3 weeks of treatment (44 days after implantation) animals were killed, and tumor sizes and weights were measured. Furthermore, a part of the primary tumors as well as lung, liver, inguinal lymph nodes and lumbar spine as potential target organs for metastases were harvested, homogenized and assayed for luciferase activity as a measure for tumor cell content. Finally, blood was collected from the animals, and serum PSA levels were measured with a nephelometric immunoassay from Abbott (Wiesbaden, Germany) as a luciferase-independent biomarker for total tumor cell quantification.
As shown in Figure 2a , animals of all three groups lost weight during the experiment. The weight loss started before treatment, suggesting primary tumor burden or the metastatic spread of the tumor cells rather than the treatment as a possible cause (see supporting information). Following the onset of treatment on day 25, the decrease in body weights was most pronounced in the group treated with doxorubicin, and one animal died in this group on day 25. For the control group, in which two animals died during the course of the experiment, tumor-related problems were the most likely cause for their demise, whereas a combination of tumor burden and treatment may have been the cause in the case of doxorubicin.
BLI measurements of the luciferase-expressing LNCaP LLN cells were used to assess the growth of the tumor once weekly. The in vivo BLI activity of the treated groups was higher than that of the control group (Figure 2b) . The most likely reason for these differences is attributed to the above-mentioned deaths of the two animals in the control group and one in the doxorubicintreated group (see Table 1 ), which most likely reduced the total average tumor sizes in these groups. In addition, with increasing tumor sizes, the linearity of the BLI signal decreases because of an increase in necrotic areas and a saturation of the signal.
In contrast to in vivo BLI measurements, callipered tumor sizes and the luciferase assay at the end of the In vivo growth curves as measured by bioluminescence during treatment with doxorubicin and PSA9. For luciferase in vivo measurements, animals were injected with 100 ml of D-luciferin, anesthetized, and 10 min after the injection, images of mice were acquired using a NIGHTOWL camera. Light emission over the whole animal was quantified as photons per second using the Winlight Software (Berthold Technologies).
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experiment showed an increased antitumor activity of PSA9 at 3 Â 6 mg kg À1 doxorubicin equivalents over the doxorubicin-treated and control groups-see Table 1 and Figure 3a (P ¼ 0.27 (tumor size) and P ¼ 0.1 (luciferase activity) versus control).
The most likely explanation for the apparent tumor growth-stimulating activity of doxorubicin is given above, the reduction of the control group by two animals that died during the experiment (see Figure 3a) . Last but not least, PSA serum levels confirmed the antitumor/antimetastatic effect of PSA9 with the lowest levels compared with doxorubicin and close to statistical significance versus the control group (P ¼ 0.09, Figure 3a) .
Effects on lung, liver, inguinal lymph nodes and lumbar spine metastases
Luciferase assays of potential target organs are a means to quantify metastatic tumor cells and analyze the effect of antimetastatic treatment. The use of the high luciferaseexpressing LNCaP LLN cell pool generated in this study yielded B10 times higher luciferase activities in the organs of control animals compared with the previous study, thus resulting in a more stable readout. Therapy with PSA9 produced statistically significantly reduced luciferase activities in the lung and lumbar spine when compared with control animals (see Figure 3b) . Moreover, PSA9 showed antimetastatic effects against both hepatic and lymph-node metastases, although these were not statistically significant. Doxorubicin treatment, on the other hand, did not reduce the spread of tumor cells to any of these organs (Figure 3b) .
Conversely, our previously designed PSA5 prodrug, which lacks the PABC linker, showed moderate activity against lung metastases, which was comparable with doxorubicin at 2 Â 4 mg kg
À1
, but neither treatment showed any efficacy against any other metastases (see Figure 3b ). The clearly improved antimetastatic efficacy of PSA9 is an encouraging result, considering that the major cause of death in prostate cancer patients is metastatic disease.
1,2
The reasons why some metastatic sites were more responsive to PSA9 could be that the first two metastatic sites (the lung and lumbar spine) are major targets for metastatic LNCaP cells, and therefore have a relatively high average Figure 3 The antitumor and antimetastatic activity of PSA9 compared with doxorubicin and an untreated control group and the previous data with PSA5 in the orthotopic PSA-positive model (LNCaP). 9 The mean of the control group was set at 100%, and the other values were calculated accordingly. Students' t-test was used for statistical analysis. (a) The antitumor efficacy of PSA9 as measured by callipering, tumor volume, luciferase activity and PSA serum levels. (b) Antimetastatic activities of PSA9 (bold colors) on lung, bone, lymph-node and liver metastases compared with the results from the previously reported PSA5 results, including the respective controls (light colors). 9 In this study, the lumbar spine was assayed for luciferase activity; in the previous study, the femur served as an example for bone metastases. The apparent pro-tumor and pro-metastatic effect of doxorubicin in the results from the current study must be noted, which very likely reflects the loss of two animals in the control group. It is also noteworthy that in the PSA5 study, both doxorubicin and PSA5 showed some but not statistically significant efficacy against lung metastases, but no activity against any other metastatic site. 9 Prodrug of doxorubicin B Elsadek et al luciferase activity (14 000 and 13 000 LU per mg protein). The lymph nodes and the liver (8000 and 4000 LU per mg protein, respectively) are secondary sites only, with a more variable metastasizing profile. Thus, the more stable signals from the first two sites in the control group allow for a more robust comparison between control and treatment. The size of the metastases and varying levels of proteases that cleave the prodrugs and/or the dipeptide in the different metastases are also a possible explanation. Besides achieving more stable in vitro luciferase assay results, we were hoping that the increase in luciferase activity per cell would enable the detection of signals from lung metastases in vivo. However, despite consistently high in vitro luciferase activities from the lungs of tumor-bearing control animals, no corresponding signal could be detected in vivo. One problem might be the disperse distribution of the numerous, but small metastases in the lung, which will generate a rather scattered light signal compared with the primary tumor or larger, well-defined metastases. In addition, the difference between the luciferase activities of the primary versus the lung metastases is quite large, which requires a broad dynamic range to display both signals at the same time. Recently, an alternative very sensitive method to detect tumors in vivo was developed using an a v b 3 integrinbinding fluorescent probe ('integrisense') in combination with a fluorescence molecular tomographic imaging system. 19, 20 Therefore, three animals that had not been included in the study were subjected to integrisensemediated in vivo fluorescence imaging. However, whereas the primary tumor was readily detected in vivo, lung metastases could only be seen on opening the animal's chest, and only in the animal, which displayed the highest in vitro luciferase activity (Figures 4a and b) . The quantification of the in vivo three-dimensional fluorescence imaging for the primary tumor correlated well with results from the in vivo and in vitro luciferase activities and with the actual tumor size (see Table 2 ). Thus, both sensitive in vivo tumor measurement modalities were in good agreement regarding the detection of the primary tumor, but our data indicate that more sensitive imaging probes, for example, imaging compounds that exploit the quenching effects of tumor-susceptible probes, are required to image metastases effectively. 21 In summary, incorporating the self-eliminating PABC spacer between the peptide sequence and doxorubicin improved the cleavage profile liberating free doxorubicin effectively in the PSA-positive tumor tissue. This improvement is translated preclinically in vivo in the form of a promising antitumor efficacy of PSA9 using all modes of necropsy analyses (namely tumor size, luciferase activity and PSA serum levels), although just below significance versus nontreated animals. In contrast, the clinically established doxorubicin showed no effect at all (Figure 3a) . Furthermore, luciferase assays as a mean to measure tumor cell spreading into organs for metastatic disease, demonstrated that PSA9, but not the free drug, was able to significantly decrease the metastatic spread The main graph displays a scan of the area of the primary tumor (blue square). As we did not detect any specific signal from the upper area in the analyzed animals, the animals were opened and rescanned. Only one animal gave a detectable signal in the area of the lung (green circle), which was, however, too weak for a 3D reconstruction. The three white dots are nonspecific signals from the front paws and the snout of the animals. A strong signal emanating from the primary tumors could be detected in vivo and ex vivo (orange circles). The color reproduction of this figure is available on the html full text version of the manuscript.
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of LNCaP LLN cells to the lung, liver, inguinal lymph nodes and the lumbar spine. Compared with the previous study with the PSA-cleavable prodrug PSA5, the antitumor efficacy of PSA9 on the primary tumor was comparable but the antimetastatic activity of PSA9 was considerably improved. When considering the loss of two animals of the control group in this study, the results for PSA9 seem even more impressive and indicate a clear therapeutic benefit over PSA5.
In the clinical setting, PSA levels in human primary prostate tumors can be very high depending on the stage of the disease (up to 1600-2100 nM) and 80-90% of the secreted PSA is active in the tumor environment. 22 PSA is secreted in an active form in prostate cancer but forms two stable complexes with a 1 -antichymotrypsin and a 2 -macroglobulin in the blood. PSA complexed to a 1 -antichymotrypsin is the predominant fraction of PSA. Only a minor fraction of serum PSA is not associated with proteinase inhibitors, and it is unknown whether this free fraction still has enzymatic activity. 23 In addition, it has recently been shown that PSA in mice bearing LNCaP tumors forms complexes similar to those in humans but the major immunoreactive complex contains a 1 -antitrypsin rather than a 1 -antichymotrypsin. 23 To ensure that our novel prodrug PSA9 was not being cleaved prematurely in the serum, we incubated the albumin conjugate of PSA9 with murine serum from the experiment in the LNCaP model that contains a high PSA serum level from a control tumor-bearing animal (PSA B150 ng ml
À1
) and with human serum from a patient with prostate cancer that showed a very high level of circulating PSA in his serum (PSA B718 ng ml
). As shown in Figures 5a and b , only marginal cleavage of doxorubicin or other by-products were observed over 24 h at 37 1C in either case.
Conclusions
In this study, we developed an albumin-binding prodrug of doxorubicin (PSA9) incorporating a PSA substrate that is cleaved selectively by PSA releasing doxorubicin efficiently as the final cleavage product due to the incorporation of PABC as a self-immolative spacer. The prodrug PSA9 demonstrated superior efficacy over doxorubicin regarding the tumor growth of the primary tumor and on the spread of metastases. The pronounced and statistically significant effect on lung and bone metastases is noteworthy, considering that such metastases are often responsible for the poor quality life of prostate cancer patients and mortality. In this sense, Three mice that were not included in the main study were subjected to in vivo BLI before they were injected with integrisense 750 probe (2.4 nmol per mouse). Images were quantified using NIGHTOWL (Berthold Technologies; BLI) or a Visen FMT 1500 instrument, Visen Medical, Bedford, MA, USA (fluorescence). Animals were then killed, opened and subjected again to fluorescence imaging ('in vitro'/metastases lung). Tumors and lungs were then removed, homogenized and their luciferase activity determined ('in vitro'/metastases lung). ). Reversed-phase HPLC studies were performed on a BioLogic Duo-Flow System (Munich, Germany) using a solvent delivery system (BioLogic Duo-Flow 1082), an internal UV detector (l ¼ 280 nm), an external UV detector, Bischoff Lambda 1010 (l ¼ 495 nm), a Nucleosil C18-column (100-5, 250 Â 4 mm 2 , Macherey-Nagel, Dü ren, Germany) and Bio-Rad software (Munich, Germany) for data analysis; HPLC conditions: flow rate: 1 ml per min; mobile phase A: 20% MeCN, 80% water and 0.1% HCl; mobile phase B: 50% MeCN, 50% water and 0.1% HCl: gradient: 0-5 min 100% mobile phase A; 5-35 min increase to 100% mobile phase B; 35-40 min 100% mobile phase B; 40-45 min decrease to 100% mobile phase A; 45-50 min 100% mobile phase A; injection volume: 50 ml.
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PSA9 is an optimized prodrug over PSA5 that did not release doxorubicin and showed less activity regarding the development of metastases. Nevertheless, further preclinical development of PSAcleavable prodrugs based on PSA9 as a lead structure is necessary to identify a candidate for clinical development. Considering that the primary prostate tumor grows slowly and that the spread of metastases generally occurs over a long period of time, a subsequent step in our preclinical development to further improve the efficacy of the outlined prodrug strategy for treating prostate cancer would be to investigate an improved long-acting dosing schedule with our doxorubicin prodrug using a parenteral route, as prostate tumors in the majority of cases grow over a long time span, and a three-or four-weekly dose scheme with conventional anticancer agents, which only reaches high anticancer drug peaks in the prostate tumor for a very short period, is in our opinion not an optimal way of treating slow-growing tumors. Therefore, another innovative approach that we are currently investigating in our group is the development of orally applicable albumin-binding prodrugs. Administration of such agents bearing a PSA-cleavable substrate as a longterm oral dosage form should ideally allow a continuous and critical concentration of the drug to be released in the prostate primary tumor and in metastases over a long time span, thus reducing systemic toxicity and optimizing the therapeutic outcome of our prodrug approach. Such an approach, although certainly ambitious, could transfer favorably to tumors that grow slowly such as prostate tumors and to achieve long-term stabilization or reduction in tumor growth. The development of orally applicable albumin prodrugs with PSA cleavage seems feasible and worthy of further investigation to obtain a critical cytotoxic concentration over a long and constant time span within the heterogeneous prostate tumor characterized by tumor cells in different cell cycles, which allows the patient to dose an oral prodrug according to his personal needs.
